{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T13:34:10Z","timestamp":1782480850311,"version":"3.54.5"},"reference-count":23,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,6,16]],"date-time":"2023-06-16T00:00:00Z","timestamp":1686873600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>The therapy of children with acute lymphoblastic leukemia (ALL) in limited resource geospaces is challenging and must balance safety, efficacy, availability, and affordability. We modified the control arm of the St. Jude Total XI protocol for outpatient delivery including once-weekly daunorubicin and vincristine in initial therapy, postponing intrathecal chemotherapy until day 22, prophylactic oral antibiotics\/antimycotics, use of generic drugs, and no central nervous system (CNS) radiation. Data were interrogated from 104 consecutive children \u226412 years (median, 6 years [interquartile range (IQR), 3, 9 years]. All therapies were given in an outpatient setting in 72 children. Median follow-up is 56 months (IQR 20, 126 months). A total of 88 children achieved a hematological complete remission. Median event-free survival (EFS) is 87 months [95% confidence interval (CI), 39, 60], 7.6 years in low-risk children (3.4, 8 years) whereas 2.5 years (1, 10 years) in high-risk children. The 5-year cumulative incidence of relapse (CIR) is 28% (18, 35%), 26% (14, 37%) in low-risk children and 35% (14, 52%) in high-risk children. Median survival for all subjects is not reached but must exceed 5 years. A total of 36 children relapsed at a median of 12 months (5, 23 months). Outcomes were comparable to those reported in the control arm of the Total Therapy XI study, but inferior to current treatment protocols in high-income countries. The average cost of the first 2 years of therapy was $28,500 USD compared with an average cost of approximately $150,000 USD in the US, an 80% saving. In conclusion, using an outpatient-based modification of the St. Jude Total XI protocol, we obtained good results with relatively few hospitalizations or adverse events and at a substantial saving. This model can be applied in other resource-poor geospaces.<\/jats:p>","DOI":"10.3389\/fonc.2023.1187268","type":"journal-article","created":{"date-parts":[[2023,6,16]],"date-time":"2023-06-16T05:36:15Z","timestamp":1686893775000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Therapy of childhood acute lymphoblastic leukemia in resource-poor geospaces"],"prefix":"10.3389","volume":"13","author":[{"given":"Mois\u00e9s M.","family":"Gallardo-P\u00e9rez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert Peter","family":"Gale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oscar A.","family":"Reyes-Cisneros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"S\u00e1nchez-Bonilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 A.","family":"Fern\u00e1ndez-Guti\u00e9rrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy","family":"Stock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iv\u00e1n","family":"Murrieta-\u00c1lvarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Carlos","family":"Olivares-Gazca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo J.","family":"Ruiz-Delgado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Fonseca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo J.","family":"Ruiz-Arg\u00fcelles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,6,16]]},"reference":[{"key":"B1","article-title":"Leucemias agudas","volume-title":"Fundamentos de hematolog\u00eda","author":"Ruiz-Arg\u00fcelles","year":"2021"},{"key":"B2","article-title":"En el tratamiento de leucemia aguda en m\u00e9xico se obtienen resultados tan buenos como en los pa\u00edses desarrollados; sin embargo","volume":"42","author":"Ruiz-Arg\u00fcelles","year":"1990","journal-title":"Rev Invest Clin M\u00e9x"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0215(1998)78:11+<52::AID-IJC15>3.0.CO;2-3","article-title":"Nutritional status and socioeconomic conditions as prognostic factors in the outcome of therapy in acute lymphoblastic leukemia","author":"G\u00f3mez-Almaguer","year":"1998","journal-title":"Int J Cancer"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2022.106935","article-title":"Long-term results of the treatment of adolescents and adults with acute lymphoblastic leukemia with a pediatric-inspired regimen delivered on an outpatient basis: a single institution experience","volume":"121","author":"Garc\u00eda-Villase\u00f1or","year":"2022","journal-title":"Leuk Res"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2010.529202","article-title":"Outcome of adults with acute lymphoblastic leukemia treated with a pediatric-inspired therapy: a single institution experience","volume":"52","author":"Ruiz-Delgado","year":"2011","journal-title":"Leuk Lymph"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(91)90733-6","article-title":"Improved outcome in acute lymphoblastic leukaemia with reinforced early treatment and rotational combination chemotherapy","volume":"337","author":"Rivera","year":"1991","journal-title":"Lancet"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2009.252","article-title":"Long-term results of St Jude total therapy studies 11, 12, 13A, 13B, and 14 for childhood acute lymphoblastic leukemia","volume":"24","author":"Pui","year":"2010","journal-title":"Leukemia"},{"key":"B8","article-title":"Flow cytometry in the clinical laboratory. principles, applications and problems","volume":"50","author":"Ruiz-Arg\u00fcelles","year":"1992","journal-title":"Ann Biol Clin"},{"key":"B9","first-page":"25","article-title":"Utilidad del inmunofenotipo en el diagn\u00f3stico y clasificaci\u00f3n de las leucemias agudas","volume-title":"Actualizaci\u00f3n en leucemias","author":"San-Miguel","year":"1996"},{"key":"B10","article-title":"Molecular monitoring of the treatment of patients with BCR\/ABL (+) chronic myelogenous leukemia","volume":"53","author":"Ruiz-Arg\u00fcelles","year":"2001","journal-title":"Rev Invest Cl\u00edn M\u00e9x"},{"key":"B11","article-title":"Assessment of residual disease in acute leukemia by means of polymerase chain reaction: a prospective study in a single institution","volume":"52","author":"Ruiz-Arg\u00fcelles","year":"2000","journal-title":"Rev Invest Clin M\u00e9x"},{"key":"B12","article-title":"IKAROS gene deleted b-cell acute lymphoblastic leukemia in Mexican mestizos: observations in seven patients and a short review of the literature","volume":"68","author":"Ruiz-Delgado","year":"2016","journal-title":"Rev Invest Clin"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14082021","article-title":"Recent advances in treatment options for childhood acute lymphoblastic leukemia","volume":"16","author":"Malczewska","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B14","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1056\/NEJM199802193380803","article-title":"Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia","volume":"338","author":"Evans","year":"1998","journal-title":"N Engl J Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2011.07.004","article-title":"A report about treatment refusal and abandonment in children with acute lymphoblastic leukemia in China, 1997\u20132007","volume":"35","author":"Wang","year":"2011","journal-title":"Leuk Res"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30022-X","article-title":"(44 authors).: sustainable care for children with cancer: a lancet oncology commission","volume":"21","author":"Atun","year":"2020","journal-title":"Lancet Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1080\/16078454.2022.2115437","article-title":"Cancer and nutrition among children and adolescents in low- and middle-income countries","volume":"27","author":"Barr","year":"2022","journal-title":"Hematology"},{"key":"B18","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s43046-022-00126-3","article-title":"St. Jude total therapy studies from I to XVII for childhood acute lymphoblastic leukemia: a brief review","volume":"34","author":"Omar","year":"2022","journal-title":"J Egypt Natl Canc Inst"},{"key":"B19","doi-asserted-by":"publisher","first-page":"e29366","DOI":"10.1002\/pbc.29366","article-title":"Childhood acute lymphoblastic leukemia treatment in an academic hospital in Kenya: treatment outcomes and healthcare providers\u2019 perspectives","volume":"68","author":"Olbara","year":"2021","journal-title":"Pediatr Blood Cancer"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.18203\/2349-3291.ijcp20184202","article-title":"Pattern of childhood acute leukemia presentation at a tertiary hospital in nigeria: a five-year review","volume":"5","author":"Oyesakin","year":"2018","journal-title":"Int J Contemp Pediatr"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00328-4","article-title":"Pulse therapy with vincristine and dexamethasone for childhood acute lymphoblastic leukaemia (CCCG-ALL-2015): an open-label, multicentre, randomised, phase 3, non-inferiority trial","volume":"22","author":"Yang","year":"2021","journal-title":"Lancet Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1586\/17474086.2014.949233","article-title":"Improving treatment of children with acute lymphoblastic leukemia in developing countries through technology sharing, collaboration and partnerships","volume":"7","author":"Rivera","year":"2014","journal-title":"Expert Rev Hematol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1200\/JCO.20.02529","article-title":"Total body irradiation or chemotherapy conditioning in childhood ALL: a multinational, randomized, noninferiority phase III study","volume":"39","author":"Peters","year":"2021","journal-title":"J Clin Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1187268\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,16]],"date-time":"2023-06-16T05:36:20Z","timestamp":1686893780000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1187268\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,16]]},"references-count":23,"alternative-id":["10.3389\/fonc.2023.1187268"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2023.1187268","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,16]]},"article-number":"1187268"}}